Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir

NCT03374358 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

HIV Seropositivity
Metabolic Syndrome
Fatty Liver

Interventions

DRUG: Raltegravir

Sponsor

Helsinki University Central Hospital

Collaborators

[object Object]